Որոնման արդյունքները - Oumar Sy
- Ցուցադրվում են 1 - 11 արդյունքները 11
-
1
A Phase 2 Trial of Dasatinib in Patients with Advanced HER2-Positive and/or Hormone Receptor–Positive Breast Cancer Erica L. Mayer, Jean‐François Baurain, Joseph A. Sparano, Lewis C. Strauss, Mario Campone, P. Fumoleau, Hope S. Rugo, Ahmad Awada, Oumar Sy, Antonio Llombart–Cussac
Հրապարակվել է 2011Artigo -
2
Phase 1 pharmacokinetic and drug‐interaction study of dasatinib in patients with advanced solid tumors Faye M. Johnson, Shruti Agrawal, Howard A. Burris, Lee S. Rosen, Navneet K. Dhillon, David S. Hong, Anne Blackwood‐Chirchir, Feng Luo, Oumar Sy, Sanjeev Kaul, Alberto Chiappori
Հրապարակվել է 2010Artigo -
3
Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase‐2 (<scp>JAK2</scp>), in patients with myelofibrosis and low pretreatment platelet counts Claire Harrison, Nicolaas Schaap, Alessandro M. Vannucchi, Jean‐Jacques Kiladjian, Francesco Passamonti, Sonja Zweegman, Moshe Talpaz, Srđan Verstovšek, Shelonitda Rose, Jun Zhang, Oumar Sy, Ruben A. Mesa
Հրապարակվել է 2022Artigo -
4
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4‐year follow‐up and analysis of relative progression‐free survival from the random... Meletios Α. Dimopoulos, Sagar Lonial, Keith A. Betts, Clara Chen, Miriam L. Zichlin, Alexander Brun, James Signorovitch, Dinara Makenbaeva, Sabeen Mekan, Oumar Sy, Katja Weisel, Paul G. Richardson
Հրապարակվել է 2018Artigo -
5
Duration of prone position sessions: a prospective cohort study Sébastien Jochmans, Sandie Mazerand, Jonathan Chelly, Franck Pourcine, Oumar Sy, Nathalie Thieulot-Rolin, Olivier Ellrodt, Emmanuelle Mercier des Rochettes, Gaël Michaud, Jean Serbource‐Goguel, Christophe Vinsonneau, Ly Van Vong, Mehran Monchi
Հրապարակվել է 2020Artigo -
6
Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN ra... Jorge E. Cortés, Qian Jiang, Jianxiang Wang, Jianyu Weng, Huanling Zhu, Xiaoli Liu, Andreas Hochhaus, Dong‐Wook Kim, Jerald P. Radich, Michael R. Savona, Patricia Martín-Regueira, Oumar Sy, Renuka Gurnani, Giuseppe Saglio
Հրապարակվել է 2020Artigo -
7
Novel lung imaging biomarkers and skin gene expression subsetting in dasatinib treatment of systemic sclerosis-associated interstitial lung disease Viktor Martyanov, Grace Hyun J. Kim, Wendy Hayes, Shuyan Du, Bishu Ganguly, Oumar Sy, Sun Ku Lee, Galina S. Bogatkevich, Gary L. Schieven, Elena Schiopu, Roberta Gonçalves Marangoni, Jonathan Goldin, Michael L. Whitfield, John Varga
Հրապարակվել է 2017Artigo -
8
Treatment‐free remission after dasatinib in patients with chronic myeloid leukaemia in chronic phase with deep molecular response: Final 5‐year analysis of <scp>DASFREE</scp> Neil P. Shah, Valentín García‐Gutiérrez, Antonio Jiménez‐Velasco, Sarah Larson, Susanne Saußele, Delphine Réa, François‐Xavier Mahon, Moshe Levy, María Teresa Gómez‐Casares, Michael J. Mauro, Oumar Sy, Patricia Martín-Regueira, Jeffrey H. Lipton
Հրապարակվել է 2023Artigo -
9
Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study Neil P. Shah, Valentín García‐Gutiérrez, Antonio Jiménez‐Velasco, Sarah Larson, Susanne Saußele, Delphine Réa, François‐Xavier Mahon, Moshe Levy, María Teresa Gómez‐Casares, Fabrizio Pane, Franck‐Emmanuel Nicolini, Michael J. Mauro, Oumar Sy, Patricia Martín-Regueira, Jeffrey H. Lipton
Հրապարակվել է 2019Artigo -
10
Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: <scp>ELOQUENT</scp>‐2 follow‐up and <i>post‐hoc</i> analyses on progression‐free survival an... Meletios Α. Dimopoulos, Sagar Lonial, Darrell White, Philippe Moreau, Antonio Palumbo, Jesús F. San Miguel, Ofer Shpilberg, Kenneth C. Anderson, Sebastian Grosicki, Ivan Špıčka, Adam Walter‐Croneck, Hila Magen, María‐Victoria Mateos, Andrew R. Belch, Donna Reece, Meral Beksaç, Eric Bleickardt, Valerie Poulart, Jennifer Sheng, Oumar Sy, Jessica Katz, Anil Singhal, Paul G. Richardson
Հրապարակվել է 2017Artigo -
11
Effects of Standard-Dose Prophylactic, High-Dose Prophylactic, and Therapeutic Anticoagulation in Patients With Hypoxemic COVID-19 Pneumonia Vincent Labbé, Damien Contou, Nicholas Heming, Bruno Mégarbane, Keyvan Razazi, Florence Boissier, Hafid Ait‐Oufella, Matthieu Turpin, Serge Carreira, Alexandre Robert, Mehran Monchi, Bertrand Souweine, Sébastien Préau, Denis Doyen, Emmanuel Vivier, Noémie Zucman, Martin Dres, Mohamed Fejjal, Élise Noël-Savina, Marwa Bachir, Karim Jaffal, Jean‐François Timsit, Santiago Alberto Picos, Éric Mariotte, Nihal Martis, William Juguet, Giovanna Melica, Paul Rondeau, Étienne Audureau, Armand Mekontso Dessap, Gaetan Plantefevre, Djillali Annane, Aurélien Dinh, Lilia Abdeladim, Rania Bounab, Pierre Moine, Virginie Maxime, Hayette Tessa, Miguel Carlos, Emmanuelle Kuperminc, Sébastian Voicu, Isabelle Malissin, Nicolas Deye, Aymen Mrad, Thomas Lacoste-Palasset, Thomas Lefèvre, Luc Haudebourg, Jean-Michel Ekhérian, François Bagate, Nicolas de Prost, Guillaume Carteaux, Inès Bendib, Samuel Tuffet, Julien Lopinto, Pascale Labedade, Gaêl Michaud, Brice Benelli, Anne Fleur Haudebourg, Ségolène Gendreau, Emilio Berti, Astrid Bertier, Romain Arrestier, Paul Masi, E. Dufranc, Rémi Coudroy, Arnaud W. Thille, Anne Veinstein, Delphine Chatellier, Jean‐Pierre Frat, Maeva Rodriguez, Faustine Reynaud, Victor De Roubin, François Arrivé, Paul Gabarre, Diane Bollens, Patrick Ingiliz, Bénédicte Lefebvre, Zineb Ouazene, Thibault Chiarabini, Nadia Valin, Tomas Urbina, Vincent Bonny, Naïke Bigé, Karine Lacombe, Muriel Fartoukh, Cyrielle Desnos, Guillaume Voiriot, Michel Djibré, Clarisse Blayau, Aude Gibelin, Julien Dessajan, Ludovic Lassel, Pierre-Marie Bertrand, Raphael Chambon, Nicolas Clément, Oumar Sy, Sébastien Jochmans, Claire Dupuis, Laure Calvet, François Thouy
Հրապարակվել է 2023Artigo
Որոնման գործիքներ:
Առնչվող խորագիր
Internal medicine
Medicine
Dasatinib
Gastroenterology
Oncology
Adverse effect
Imatinib
Myeloid leukemia
Randomized controlled trial
Receptor
Surgery
Cancer
Chemotherapy
Tyrosine kinase
Chronic myeloid leukaemia
Clinical endpoint
Clinical trial
Confidence interval
Dexamethasone
Discontinuation
Hazard ratio
Lenalidomide
Lung
Multiple myeloma
Pathology
Progression-free survival
Tyrosine-kinase inhibitor
ARDS
Alternative medicine
Anesthesia